Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 1 December 2023, including: CAR-Ts and malignancies; comeback for GSK plc’s Blenrep?; Novartis AG’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation" - Scrip, 29 Nov, 2023.)
(Also see "Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain" - Scrip, 27 Nov, 2023.)
(Also see "Novartis Has A New Goal: $2bn Peak Sales Per Product" - Scrip, 28 Nov, 2023.)
(Also see "Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?" - Scrip, 29 Nov, 2023.)
(Also see "Scrip Awards Lifetime Achievement Winner Jeremy Levin Urges Pharma To Put Humanity First" - Scrip, 24 Nov, 2023.)